Sign In
ONCE-WEEKLY VS TWICE-WEEKLY CARFILZOMIB DOSING PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS OF THE RANDOMIZED PHASE 3 STUDY A.R.R.O.W.
Author(s): ,
Maria-Victoria Mateos
Affiliations:
Hematology,Hospital Clinico Universitario de Salamanca-IBSAL,Salamanca,Spain
,
Philippe Moreau
Affiliations:
Hematology Department,University of Nantes,Nantes,France
,
James R. Berenson
Affiliations:
Institute for Myeloma and Bone Cancer Research,West Hollywood,United States
,
Katja Weisel
Affiliations:
Universitatsklinikum Tubingen,Tubingen,Germany
,
Antonio Lazzaro
Affiliations:
Department of Clinical Oncology and Hematology, Division of Hematology and Bone Marrow Transplant Center,Hospital Gulielmo da Saliceto,Piacenza,Italy
,
Kevin Song
Affiliations:
Leukemia/Bone Marrow Transplant Program of British Columbia,Vancouver,Canada
,
Meletios A. Dimopoulos
Affiliations:
National and Kapodistrian University of Athens,Athens,Greece
,
Mei Huang
Affiliations:
Amgen Inc.,Thousand Oaks,United States
,
Anita Zahlten-Kumeli
Affiliations:
Amgen Inc.,Thousand Oaks,United States
A. Keith Stewart
Affiliations:
Division of Hematology/Oncology, Mayo Clinic,Scottsdale,United States
EHA Library. Victoria Mateos M.
Jun 16, 2018; 214544
Maria Victoria Mateos
Maria Victoria Mateos
Contributions
×
Abstract

Abstract: S849

Type: Oral Presentation

Presentation during EHA23: On Saturday, June 16, 2018 from 16:30 - 16:45

Location: Room A1

Background
Twice-weekly carfilzomib (K) at 20/27 mg/m2 is approved for the treatment of RRMM. To develop a more convenient K regimen, once-weekly K plus dexamethasone (d) was assessed in the phase 1/2 CHAMPION-1 study, establishing a maximum tolerated dose of K 20/70 mg/m2 for RRMM pts.

Aims
To present results from the pre-planned interim analysis of the phase 3 study A.R.R.O.W. comparing Kd once-weekly at 20/70 mg/m2 (once-weekly group) vs twice-weekly at 20/27 mg/m2 (twice-weekly group).

Methods
Pts with 2–3 prior therapies and prior exposure to proteasome inhibitor and immunomodulatory agent were eligible. Pts were randomized 1:1 to receive either once- or twice-weekly K plus d. The once-weekly group received K (30-min IV) on days (D) 1, 8, and 15 of all cycles (20 mg/m2 on D1 [cycle 1]; 70 mg/m2 thereafter). The twice-weekly group received K (10-min IV) on D1, 2, 8, 9, 15, and 16 (20 mg/m2 on D1 and 2 during cycle 1 and 27 mg/m2 thereafter). All pts received d at 40 mg on D1, 8, 15 (all cycles), and 22 (cycle 1–9 only). Treatment was given in 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall response rate (ORR), overall survival, safety, and pharmacokinetics.

Results
Baseline characteristics were generally balanced. Median PFS (once- vs twice-weekly) was 11.2 mo vs 7.6 mo (hazard ratio = 0.69; 1-sided P=0.0014). ORR (once- vs twice-weekly) was 62.9% vs 40.8% (P<0.0001); 7.1% vs 1.7% had a complete response or better. Grade ≥3 adverse events (AEs) occurred in 67.6% (once-weekly) and 61.7% (twice-weekly). Treatment-related grade 5 AEs occurred in 5 pts (2.1%) (once-weekly) and 2 pts (0.9%) (twice-weekly). The incidence of grade ≥3 hypertension and cardiac failure (once- vs twice-weekly) was 5.9% vs 5.5% and 2.9% vs 4.3%, respectively.

Conclusion
Once-weekly Kd at 20/70 mg/m2 significantly improved PFS and ORR vs twice-weekly Kd at 20/27 mg/m2. The incidence of AEs was comparable between groups. No new safety risks were found in the once-weekly group. Overall, once-weekly Kd showed favorable benefit-risk profile with a convenient dosing regimen vs twice-weekly Kd.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Clinical Trial, Multiple Myeloma, Phase III, Proteasome inhibitor

Premium Sponsors
Major Sponsors

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies